

NCT Heidelberg | Im Neuenheimer Feld 460 | D-69120 Heidelberg

To

Baishideng Publishing Group

Dr. med. Georg Martin Haag

Oberarzt

Medizinische Onkologie

Im Neuenheimer Feld 460

69120 Heidelberg

Tel +49 (0)6221 56 8819

Fax+49 (0)6221 56 33853

GeorgMartin.Haag@med.uni-heidelberg.de

Heidelberg, 04.07.2020

Manuscript: Cancer-related microangiopathic hemolytic anaemia (CR-MAHA) in patients with advanced gastric cancer: a retrospective cohort study

Explanation of Statistical Analysis

Categorical data are presented with frequencies and percentages.

Continuous data are summarized with at least the following: median, minimum and maximum.

Progression free survival (PFS) is defined as time from CR-MAHA diagnosis until documented tumor progression or death.

Overall survival (OS) is defined as the time from CR-MAHA diagnosis to death.

Residual survival is defined as the time from start of secondline therapy to death.

Time-to event data are analyzed using standard methods, including Kaplan-Meier product-limit estimate.

Statistical analyses were performed using SPSS statistical software, Version 25.

All statistical analyses have been reviewed by a second independent physician.

Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg

Im Neuenheimer Feld 460

D-69120 Heidelberg

www.nct-heidelberg.de

Onkologische Sprechstunden

Allgemeine Onkologie

CUP (Cancer of Unknown Primary)

Dermatologische Tumoren

Gastrointestinale Tumoren

Gynäkologische Tumoren

Gynäkologisch-genetische Sprechstunde

Kopf-Hals Tumoren

Kinderonkologie

Leukämie

Lymphome

Myelome

Neuroendokrine Tumoren

Neuroonkologie

Radioonkologie

Sarkome

Thorakale Tumoren

Urologische Tumoren

Beratungen

Krebsinformationsdienst (KID)

Ernährung

Psychoonkologie

Sozialdienst

Bewegung und Krebs

Geschäftsführende Direktoren

Prof. Dr. Stefan Fröhling (komm.)

Präzisionsonkologie, Deutsches

Krebsforschungszentrum (DKFZ)

Prof. Dr. Dirk Jäger

Medizinische Onkologie,

Universitätsklinikum Heidelberg (U

Stellvertretende Direktoren

Prof. Dr. Peter Lichter

Molekulare Genetik, Deutsches

Krebsforschungszentrum (DKFZ)

Prof. Dr. Jürgen Debus

Radioonkologie, Universitätsklinikum

Heidelberg (UKHD)

04.07.2020

